Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Nuclear Cardiology
Published in: Journal of Nuclear Cardiology 6/2016

01-12-2016 | Review Article

The role of nuclear cardiac imaging in risk stratification of sudden cardiac death

Authors: Daniel Juneau, MD, FRCPC, Fernanda Erthal, MD, Benjamin J. W. Chow, MD, FRCPC, FACC, FASNC, Calum Redpath, MBChB, PhD, Terrence D. Ruddy, MD, FRCPC, FACC, FASNC, Juhani Knuuti, MD, PhD, Rob S. Beanlands, MD, FRCPC, FACC

Published in: Journal of Nuclear Cardiology | Issue 6/2016

Login to get access

Abstract

Sudden cardiac death (SCD) represents a significant portion of all cardiac deaths. Current guidelines focus mainly on left ventricular ejection fraction (LVEF) as the main criterion for SCD risk stratification and management. However, LVEF alone lacks both sensitivity and specificity in stratifying patients. Recent research has provided interesting data which supports a greater role for advanced cardiac imaging in risk stratification and patient management. In this article, we will focus on nuclear cardiac imaging, including left ventricular function assessment, myocardial perfusion imaging, myocardial blood flow quantification, metabolic imaging, and neurohormonal imaging. We will discuss how these can be used to better understand SCD and better stratify patient with both ischemic and non-ischemic cardiomyopathy.
Appendix
Available only for authorised users
Literature
1.
Zheng Z-J, Croft JB, Giles WH, Mensah GA. Sudden cardiac death in the United States, 1989 to 1998. Circulation 2001;104:2158-63.PubMedCrossRef
2.
Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. Heart disease and stroke statistics—2015 update: A report from the American Heart Association. Circulation 2015;131:e29-322.PubMedCrossRef
3.
Myerburg RJ, Mitrani R, Interian A, Castellanos A. Interpretation of outcomes of antiarrhythmic clinical trials: Design features and population impact. Circulation 1998;97:1514-21.PubMedCrossRef
4.
5.
6.
7.
8.
Tracy CM, Epstein AE, Darbar D, DiMarco JP, Dunbar SB, Estes NAM, et al. 2012 ACCF/AHA/HRS focused update of the 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2012;60:1297-313.PubMedCrossRef
9.
Priori SG, Blomström-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J, et al. 2015 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC) Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J 2015;36:2793-867.PubMedCrossRef
10.
Stecker EC, Vickers C, Waltz J, Socoteanu C, John BT, Mariani R, et al. Population-based analysis of sudden cardiac death with and without left ventricular systolic dysfunction. Two-year findings from the oregon sudden unexpected death study. J Am Coll Cardiol 2006;47:1161-6.PubMedCrossRef
11.
Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002;346:877-83.PubMedCrossRef
12.
Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005;352:225-37.PubMedCrossRef
13.
Moss AJ, Greenberg H, Case RB, Zareba W, Hall WJ, Brown MW, et al. Long-term clinical course of patients after termination of ventricular tachyarrhythmia by an implanted defibrillator. Circulation 2004;110:3760-5.PubMedCrossRef
14.
Bertini M, Schalij MJ, Bax JJ, Delgado V. Emerging role of multimodality imaging to evaluate patients at risk for sudden cardiac death. Circ Cardiovasc Imaging 2012;5:525-35.PubMedCrossRef
15.
Olshausen KV, Witt T, Pop T, Treese N, Bethge K-P, Meyer J. Sudden cardiac death while wearing a Holter monitor. Am J Cardiol 1991;67:381-6.PubMedCrossRef
16.
Thomsen PEB, Jons C, Raatikainen MJP, Joergensen RM, Hartikainen J, Virtanen V, et al. Long-term recording of cardiac arrhythmias with an implantable cardiac monitor in patients with reduced ejection fraction after acute myocardial infarction the cardiac arrhythmias and risk stratification after acute myocardial infarction (CARISMA) study. Circulation 2010;122:1258-64.CrossRef
17.
Kuck KH, Cappato R, Siebels J, Rüppel R. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: The Cardiac Arrest Study Hamburg (CASH). Circulation 2000;102:748-54.PubMedCrossRef
18.
Connolly SJ, Gent M, Roberts RS, Dorian P, Roy D, Sheldon RS, et al. Canadian implantable defibrillator study (CIDS): A randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation 2000;101:1297-302.PubMedCrossRef
19.
McAnulty J, Halperin B, Kron J, Larsen G, Rait M, Swenson R, et al. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 1997;337:1576-84.CrossRef
20.
21.
Luqman N, Sung RJ, Wang C-L, Kuo C-T. Myocardial ischemia and ventricular fibrillation: Pathophysiology and clinical implications. Int J Cardiol 2007;119:283-90.PubMedCrossRef
22.
23.
Cao JM, Fishbein MC, Han JB, Lai WW, Lai AC, Wu TJ, et al. Relationship between regional cardiac hyperinnervation and ventricular arrhythmia. Circulation 2000;101:1960-9.PubMedCrossRef
24.
Risk stratification and survival after myocardial infarction. N Engl J Med 1983;309:331-6.CrossRef
25.
Gradman A, Deedwania P, Cody R, Massie B, Packer M, Pitt B, et al. Predictors of total mortality and sudden death in mild to moderate heart failure. Captopril-Digoxin Study Group. J Am Coll Cardiol 1989;14:564-70; discussion 571-572.PubMedCrossRef
26.
Curtis JP, Sokol SI, Wang Y, Rathore SS, Ko DT, Jadbabaie F, et al. The association of left ventricular ejection fraction, mortality, and cause of death in stable outpatients with heart failure. J Am Coll Cardiol 2003;42:736-42.PubMedCrossRef
27.
Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Hafley G. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med 1999;341:1882-90.PubMedCrossRef
28.
Dickstein K, Vardas PE, Auricchio A, Daubert J-C, Linde C, McMurray J, et al. 2010 Focused Update of ESC Guidelines on device therapy in heart failure: An update of the 2008 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC guidelines for cardiac and resynchronization therapy Developed with the special contribution of the Heart Failure Association and the European Heart Rhythm Association. Eur Heart J 2010;31:2677-87.PubMedCrossRef
29.
Epstein AE, DiMarco JP, Ellenbogen KA, Estes NAM, Freedman RA, Gettes LS, et al. ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): Developed in Collaboration With the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation 2008;117:e350-408.PubMedCrossRef
30.
Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH, et al. 2013 ACCF/AHA Guideline for the management of heart failure: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013;128:e240-327.PubMedCrossRef
31.
Zipes DP, Camm AJ, Borggrefe M, Buxton AE, Chaitman B, Fromer M, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death): Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006;114:e385-484.PubMedCrossRef
32.
Hachamovitch R, Rozanski A, Hayes SW, Thomson LEJ, Germano G, Friedman JD, et al. Predicting therapeutic benefit from myocardial revascularization procedures: Are measurements of both resting left ventricular ejection fraction and stress-induced myocardial ischemia necessary? J Nucl Cardiol 2006;13:768-78.PubMedCrossRef
33.
Lertsburapa K, Ahlberg AW, Bateman TM, Katten D, Volker L, Cullom SJ, et al. Independent and incremental prognostic value of left ventricular ejection fraction determined by stress gated rubidium 82 PET imaging in patients with known or suspected coronary artery disease. J Nucl Cardiol 2008;15:745-53.PubMedCrossRef
34.
Hendel RC, Berman DS, Di Carli MF, Heidenreich PA, Henkin RE, Pellikka PA, et al. ACCF/ASNC/ACR/AHA/ASE/SCCT/SCMR/SNM 2009 appropriate use criteria for cardiac radionuclide imaging. J Am Coll Cardiol 2009;53:2201-29.PubMedCrossRef
35.
Corbett JR, Akinboboye OO, Bacharach SL, Borer JS, Botvinick EH, DePuey EG, et al. ASNC imaging guidelines for nuclear cardiology procedures. J Nucl Cardiol 2009;16:164.CrossRef
36.
Harel F, Finnerty V, Grégoire J, Thibault B, Marcotte F, Ugolini P, et al. Gated blood-pool SPECT versus cardiac magnetic resonance imaging for the assessment of left ventricular volumes and ejection fraction. J Nucl Cardiol 2010;17:427-34.PubMedCrossRef
37.
Akinboboye O, Nichols K, Wang Y, Dim UR, Reichek N. Accuracy of radionuclide ventriculography assessed by magnetic resonance imaging in patients with abnormal left ventricles. J Nucl Cardiol 2005;12:418-27.PubMedCrossRef
38.
Schaefer WM, Lipke CSA, Standke D, Kühl HP, Nowak B, Kaiser H-J, et al. Quantification of left ventricular volumes and ejection fraction from gated 99mTc-MIBI SPECT: MRI validation and comparison of the Emory Cardiac Tool Box with QGS and 4D-MSPECT. J Nucl Med 2005;46:1256-63.PubMed
39.
Wackers FJ, Berger HJ, Johnstone DE, Goldman L, Reduto LA, Langou RA, et al. Multiple gated cardiac blood pool imaging for left ventricular ejection fraction: Validation of the technique and assessment of variability. Am J Cardiol 1979;43:1159-66.PubMedCrossRef
40.
41.
Huikuri HV, Castellanos A, Myerburg RJ. Sudden death due to cardiac arrhythmias. N Engl J Med 2001;345:1473-82.PubMedCrossRef
42.
Kelly P, Ruskin JN, Vlahakes GJ, Buckley MJ, Freeman CS, Garan H. Surgical coronary revascularization in survivors of prehospital cardiac arrest: Its effect on inducible ventricular arrhythmias and long-term survival. J Am Coll Cardiol 1990;15:267-73.PubMedCrossRef
43.
Holmes DR, Davis KB, Mock MB, Fisher LD, Gersh BJ, Killip T, et al. The effect of medical and surgical treatment on subsequent sudden cardiac death in patients with coronary artery disease: a report from the Coronary Artery Surgery Study. Circulation 1986;73:1254-63.PubMedCrossRef
44.
van der Burg AEB. Impact of viability, ischemia, scar tissue, and revascularization on outcome after aborted sudden death. Circulation 2003;108:1954-9.PubMedCrossRef
45.
Hachamovitch R, Berman DS, Shaw LJ, Kiat H, Cohen I, Cabico JA, et al. Incremental prognostic value of myocardial perfusion single photon emission computed tomography for the prediction of cardiac death differential stratification for risk of cardiac death and myocardial infarction. Circulation 1998;97:535-43.PubMedCrossRef
46.
Piccini JP, Horton JR, Shaw LK, Al-Khatib SM, Lee KL, Iskandrian AE, et al. Single-photon emission computed tomography myocardial perfusion defects are associated with an increased risk of all-cause death, cardiovascular death, and sudden cardiac death. Circ Cardiovasc Imaging 2008;1:180-8.PubMedCrossRef
47.
Piccini JP, Starr AZ, Horton JR, Shaw LK, Lee KL, Al-Khatib SM, et al. Single-photon emission computed tomography myocardial perfusion imaging and the risk of sudden cardiac death in patients with coronary disease and left ventricular ejection fraction > 35%. J Am Coll Cardiol 2010;56:206-14.PubMedCrossRef
48.
Paganelli F, Barnay P, Imbert-Joscht I, Gelisse R, Saadjian A, Mundler O, et al. Influence of residual myocardial ischaemia on induced ventricular arrhythmias following a first acute myocardial infarction. Eur Heart J 2001;22:1931-7.PubMedCrossRef
49.
McArdle BA, Dowsley TF, deKemp RA, Wells GA, Beanlands RS. Does rubidium-82 PET have superior accuracy to SPECT perfusion imaging for the diagnosis of obstructive coronary disease? A systematic review and meta-analysis. J Am Coll Cardiol 2012;60:1828-37.CrossRef
50.
Parker MW, Iskandar A, Limone B, Perugini A, Kim H, Jones C, et al. Diagnostic accuracy of cardiac positron emission tomography versus single photon emission computed tomography for coronary artery disease: A bivariate meta-analysis. Circ Cardiovasc Imaging 2012;5:700-7.PubMedCrossRef
51.
52.
Dorbala S, Di Carli MF, Beanlands RS, Merhige ME, Williams BA, Veledar E, et al. Prognostic value of stress myocardial perfusion positron emission tomography. J Am Coll Cardiol 2013;61:176-84.PubMedCrossRef
53.
Lortie M, Beanlands RSB, Yoshinaga K, Klein R, Dasilva JN, DeKemp RA. Quantification of myocardial blood flow with 82Rb dynamic PET imaging. Eur J Nucl Med Mol Imaging 2007;34:1765-74.PubMedCrossRef
54.
Rijnierse MT, de Haan S, Harms HJ, Robbers LF, Wu L, Danad I, et al. Impaired hyperemic myocardial blood flow is associated with inducibility of ventricular arrhythmia in ischemic cardiomyopathy. Circ Cardiovasc Imaging 2014;7:20-30.PubMedCrossRef
55.
De Bakker JM, Van Capelle FJ, Janse MJ, Wilde AA, Coronel R, Becker AE, et al. Reentry as a cause of ventricular tachycardia in patients with chronic ischemic heart disease: Electrophysiologic and anatomic correlation. Circulation 1988;77:589-606.PubMedCrossRef
56.
Bello D, Fieno DS, Kim RJ, Pereles FS, Passman R, Song G, et al. Infarct morphology identifies patients with substrate for sustained ventricular tachycardia. J Am Coll Cardiol 2005;45:1104-8.PubMedCrossRef
57.
Machecourt J, Longère P, Fagret D, Vanzetto G, Wolf JE, Polidori C, et al. Prognostic value of thallium-201 single-photon emission computed tomographic myocardial perfusion imaging according to extent of myocardial defect: Study in 1,926 patients with foilow-up at 33 months. J Am Coll Cardiol 1994;23:1096-106.PubMedCrossRef
58.
Morishima I, Sone T, Tsuboi H, Mukawa H, Uesugi M, Morikawa S, et al. Risk stratification of patients with prior myocardial infarction and advanced left ventricular dysfunction by gated myocardial perfusion SPECT imaging. J Nucl Cardiol 2008;15:631-7.PubMedCrossRef
59.
Di Carli MF, Maddahi J, Rokhsar S, Schelbert HR, Bianco-Batlles D, Brunken RC, et al. Long-term survival of patients with coronary artery disease and left ventricular dysfunction: Implications for the role of myocardial viability assessment in management decisions. J Thorac Cardiovasc Surg 1998;116:997-1004.PubMedCrossRef
60.
Di Carli MF, Davidson M, Little R, Khanna S, Mody FV, Brunken RC, et al. Value of metabolic imaging with positron emission tomography for evaluating prognosis in patients with coronary artery disease and left ventricular dysfunction. Am J Cardiol 1994;73:527-33.PubMedCrossRef
61.
Desideri A, Cortigiani L, Christen AI, Coscarelli S, Gregori D, Zanco P, et al. The extent of perfusion-F18-fluorodeoxyglucose positron emission tomography mismatch determines mortality in medically treated patients with chronic ischemic left ventricular dysfunction. J Am Coll Cardiol 2005;46:1264-9.PubMedCrossRef
62.
Beanlands RSB, Nichol G, Huszti E, Humen D, Racine N, Freeman M, et al. F-18-fluorodeoxyglucose positron emission tomography imaging-assisted management of patients with severe left ventricular dysfunction and suspected coronary disease. J Am Coll Cardiol 2007;50:2002-12.PubMedCrossRef
63.
Uebleis C, Hellweger S, Laubender RP, Becker A, Sohn H-Y, Lehner S, et al. The amount of dysfunctional but viable myocardium predicts long-term survival in patients with ischemic cardiomyopathy and left ventricular dysfunction. Int J Cardiovasc Imaging 2013;29:1645-53.PubMedCrossRef
64.
Ling LF, Marwick TH, Flores DR, Jaber WA, Brunken RC, Cerqueira MD, et al. Identification of therapeutic benefit from revascularization in patients with left ventricular systolic dysfunction: Inducible ischemia versus hibernating myocardium. Circ Cardiovasc Imaging 2013;6:363-72.PubMedCrossRef
65.
Bonow RO, Maurer G, Lee KL, Holly TA, Binkley PF, Desvigne-Nickens P, et al. Myocardial viability and survival in ischemic left ventricular dysfunction. N Engl J Med 2011;364:1617-25.PubMedPubMedCentralCrossRef
66.
Mielniczuk LM, Beanlands RS. Does imaging-guided selection of patients with ischemic heart failure for high risk revascularization improve identification of those with the highest clinical benefit? Imaging-guided selection of patients with ischemic heart failure for high-risk revascularization improves identification of those with the highest clinical benefit. Circ Cardiovasc Imaging 2012;5:262-70; discussion 270.PubMedCrossRef
67.
Nakajo M, Shapiro B, Copp J, Kalff V, Gross MD, Sisson JC, et al. The normal and abnormal distribution of the adrenomedullary imaging agent m-[I-131]iodobenzylguanidine (I-131 MIBG) in man: Evaluation by scintigraphy. J Nucl Med 1983;24:672-82.PubMed
68.
Hattori N, Schwaiger M. Metaiodobenzylguanidine scintigraphy of the heart: What have we learnt clinically? Eur J Nucl Med 2000;27:1-6.PubMedCrossRef
69.
Bombardieri E, Giammarile F, Aktolun C, Baum RP, Bischof Delaloye A, Maffioli L, et al. 131I/123I-metaiodobenzylguanidine (mIBG) scintigraphy: Procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging 2010;37:2436-46.PubMedCrossRef
70.
71.
Sasano T, Abraham MR, Chang K-C, Ashikaga H, Mills KJ, Holt DP, et al. Abnormal sympathetic innervation of viable myocardium and the substrate of ventricular tachycardia after myocardial infarction. J Am Coll Cardiol 2008;51:2266-75.PubMedCrossRef
72.
Brunner-La Rocca HP, Esler MD, Jennings GL, Kaye DM. Effect of cardiac sympathetic nervous activity on mode of death in congestive heart failure. Eur Heart J 2001;22:1136-43.PubMedCrossRef
73.
Bax JJ, Kraft O, Buxton AE, Fjeld JG, Parízek P, Agostini D, et al. 123 I-mIBG scintigraphy to predict inducibility of ventricular arrhythmias on cardiac electrophysiology testing: A prospective multicenter pilot study. Circ Cardiovasc Imaging 2008;1:131-40.PubMedCrossRef
74.
Jacobson AF, Senior R, Cerqueira MD, Wong ND, Thomas GS, Lopez VA, et al. Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study. J Am Coll Cardiol 2010;55:2212-21.PubMedCrossRef
75.
Verberne HJ, Brewster LM, Somsen GA, van Eck-Smit BLF. Prognostic value of myocardial 123I-metaiodobenzylguanidine (MIBG) parameters in patients with heart failure: A systematic review. Eur Heart J 2008;29:1147-59.PubMedCrossRef
76.
Narula J, Gerson M, Thomas GS, Cerqueira MD, Jacobson AF. 123I-MIBG imaging for prediction of mortality and potentially fatal events in heart failure: The ADMIRE-HFX study. J Nucl Med 2015;56:1011-8.PubMedCrossRef
77.
Boogers MJ, Borleffs CJW, Henneman MM, van Bommel RJ, van Ramshorst J, Boersma E, et al. Cardiac sympathetic denervation assessed with 123-iodine metaiodobenzylguanidine imaging predicts ventricular arrhythmias in implantable cardioverter-defibrillator patients. J Am Coll Cardiol 2010;55:2769-77.PubMedCrossRef
78.
Kawai T, Yamada T, Tamaki S, Morita T, Furukawa Y, Iwasaki Y, et al. Usefulness of cardiac meta-iodobenzylguanidine imaging to identify patients with chronic heart failure and left ventricular ejection fraction < 35% at low risk for sudden cardiac death. Am J Cardiol 2015;115:1549-54.PubMedCrossRef
79.
Shah AM, Bourgoun M, Narula J, Jacobson AF, Solomon SD. Influence of ejection fraction on the prognostic value of sympathetic innervation imaging with iodine-123 MIBG in heart failure. JACC Cardiovasc Imaging 2012;5:1139-46.PubMedCrossRef
80.
Tamaki S, Yamada T, Okuyama Y, Morita T, Sanada S, Tsukamoto Y, et al. Cardiac iodine-123 metaiodobenzylguanidine imaging predicts sudden cardiac death independently of left ventricular ejection fraction in patients with chronic heart failure and left ventricular systolic dysfunction: Results from a comparative study with signal-averaged electrocardiogram, heart rate variability, and QT dispersion. J Am Coll Cardiol 2009;53:426-35.PubMedCrossRef
81.
Kasama S, Toyama T, Sumino H, Nakazawa M, Matsumoto N, Sato Y, et al. Prognostic value of serial cardiac 123I-MIBG imaging in patients with stabilized chronic heart failure and reduced left ventricular ejection fraction. J Nucl Med 2008;49:907-14.PubMedCrossRef
82.
Minardo JD, Tuli MM, Mock BH, Weiner RE, Pride HP, Wellman HN, et al. Scintigraphic and electrophysiological evidence of canine myocardial sympathetic denervation and reinnervation produced by myocardial infarction or phenol application. Circulation 1988;78:1008-19.PubMedCrossRef
83.
Simões MV, Barthel P, Matsunari I, Nekolla SG, Schömig A, Schwaiger M, et al. Presence of sympathetically denervated but viable myocardium and its electrophysiologic correlates after early revascularised, acute myocardial infarction. Eur Heart J 2004;25:551-7.PubMedCrossRef
84.
Inoue H, Zipes DP. Results of sympathetic denervation in the canine heart: Supersensitivity that may be arrhythmogenic. Circulation 1987;75:877-87.PubMedCrossRef
85.
86.
Rosenspire KC, Haka MS, Van Dort ME, Jewett DM, Gildersleeve DL, Schwaiger M, et al. Synthesis and preliminary evaluation of carbon-11-meta-hydroxyephedrine: A false transmitter agent for heart neuronal imaging. J Nucl Med 1990;31:1328-34.PubMed
87.
Allman KC, Wieland DM, Muzik O, Degrado TR, Wolfe ER, Schwaiger M. Carbon-11 hydroxyephedrine with positron emission tomography for serial assessment of cardiac adrenergic neuronal function after acute myocardial infarction in humans. J Am Coll Cardiol 1993;22:368-75.PubMedCrossRef
88.
Matsunari I, Schricke U, Bengel FM, Haase H-U, Barthel P, Schmidt G, et al. Extent of cardiac sympathetic neuronal damage is determined by the area of ischemia in patients with acute coronary syndromes. Circulation 2000;101:2579-85.PubMedCrossRef
89.
Canty JM. Hibernating myocardium: Chronically adapted to ischemia but vulnerable to sudden death. Circ Res 2004;94:1142-9.PubMedCrossRef
90.
Luisi AJ Jr, Suzuki G, DeKemp R, Haka MS, Toorongian SA, Canty Jr JM, et al. Regional 11C-hydroxyephedrine retention in hibernating myocardium: Chronic inhomogeneity of sympathetic innervation in the absence of infarction. J Nucl Med 2005;46:1368-74.PubMed
91.
Pietilä M, Malminiemi K, Ukkonen H, Saraste M, Någren K, Lehikoinen P, et al. Reduced myocardial carbon-11 hydroxyephedrine retention is associated with poor prognosis in chronic heart failure. Eur J Nucl Med 2001;28:373-6.PubMedCrossRef
92.
Fallavollita JA, Heavey BM, Luisi AJ, Michalek SM, Baldwa S, Mashtare TL, et al. Regional myocardial sympathetic denervation predicts the risk of sudden cardiac arrest in ischemic cardiomyopathy. J Am Coll Cardiol 2014;63:141-9.PubMedCrossRef
93.
Matsunari I, Aoki H, Nomura Y, Takeda N, Chen W-P, Taki J, et al. Iodine-123 metaiodobenzylguanidine imaging and carbon-11 hydroxyephedrine positron emission tomography compared in patients with left ventricular dysfunction. Circ Cardiovasc Imaging 2010;3:595-603.PubMedCrossRef
94.
Rischpler C, Fukushima K, Isoda T, Holt D, Dannals R, Bengel F, et al. Comparison of the sympathetic nerve imaging tracers hydroxyephedrine (HED) and metaiodobenzylguanidine (MIBG) in rat hearts. J Nucl Med 2011;52:332.
95.
Luisi AJ, Fallavollita JA, Suzuki G, Canty JM. Spatial inhomogeneity of sympathetic nerve function in hibernating myocardium. Circulation 2002;106:779-81.PubMedCrossRef
96.
Tamburro P, Wilber D. Sudden death in idiopathic dilated cardiomyopathy. Am Heart J 1992;124:1035-45.PubMedCrossRef
97.
Kasama S, Toyama T, Kaneko Y, Iwasaki T, Sumino H, Kumakura H, et al. Relationship between late ventricular potentials and myocardial 123I-metaiodobenzylguanidine scintigraphy in patients with dilated cardiomyopathy with mild to moderate heart failure: Results of a prospective study of sudden death events. Eur J Nucl Med Mol Imaging 2012;39:1056-64.PubMedCrossRef
98.
Manrique A, Bernard M, Hitzel A, Bauer F, Ménard J-F, Sabatier R, et al. Prognostic value of sympathetic innervation and cardiac asynchrony in dilated cardiomyopathy. Eur J Nucl Med Mol Imaging 2008;35:2074-81.PubMedCrossRef
99.
Neglia D, Michelassi C, Trivieri MG, Sambuceti G, Giorgetti A, Pratali L, et al. Prognostic role of myocardial blood flow impairment in idiopathic left ventricular dysfunction. Circulation 2002;105:186-93.PubMedCrossRef
100.
Majmudar MD, Murthy VL, Shah RV, Kolli S, Mousavi N, Foster CR, et al. Quantification of coronary flow reserve in patients with ischaemic and non-ischaemic cardiomyopathy and its association with clinical outcomes. Eur Heart J Cardiovasc Imaging 2015;16:900-9.PubMedPubMedCentralCrossRef
101.
Rijnierse MT, Allaart CP, de Haan S, Harms HJ, Huisman MC, Wu L, et al. Sympathetic denervation is associated with microvascular dysfunction in non-infarcted myocardium in patients with cardiomyopathy. Eur Heart J Cardiovasc Imaging 2015;16:788-98.PubMedCrossRef
102.
Maron BJ, Spirito P, Shen W-K, Haas TS, Formisano F, Link MS, et al. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. JAMA 2007;298:405-12.PubMed
103.
Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P, et al. 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: The task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 2014;35:2733-79.PubMedCrossRef
104.
Sorajja P, Chareonthaitawee P, Ommen SR, Miller TD, Hodge DO, Gibbons RJ. Prognostic utility of single-photon emission computed tomography in adult patients with hypertrophic cardiomyopathy. Am Heart J 2006;151:426-35.PubMedCrossRef
105.
Cecchi F, Olivotto I, Gistri R, Lorenzoni R, Chiriatti G, Camici PG. Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy. N Engl J Med 2003;349:1027-35.PubMedCrossRef
106.
Hiasa G, Hamada M, Saeki H, Ogimoto A, Ohtsuka T, Hara Y, et al. Cardiac sympathetic nerve activity can detect congestive heart failure sensitively in patients with hypertrophic cardiomyopathy. Chest 2004;126:679-86.PubMedCrossRef
107.
Matsuo S, Nakamura Y, Tsutamoto T, Kinoshita M. Impairments of myocardial sympathetic activity may reflect the progression of myocardial damage or dysfunction in hypertrophic cardiomyopathy. J Nucl Cardiol 2002;9:407-12.PubMedCrossRef
108.
Terai H, Shimizu M, Ino H, Yamaguchi M, Hayashi K, Sakata K, et al. Cardiac sympathetic nerve activity in patients with hypertrophic cardiomyopathy with malignant ventricular tachyarrhythmias. J Nucl Cardiol 2003;10:304-10.PubMedCrossRef
109.
Glaudemans AWJM, Slart RHJA, Zeebregts CJ, Veltman NC, Tio RA, Hazenberg BPC, et al. Nuclear imaging in cardiac amyloidosis. Eur J Nucl Med Mol Imaging 2009;36:702-14.PubMedCrossRef
110.
Grogan M, Dispenzieri A. Natural history and therapy of AL cardiac amyloidosis. Heart Fail Rev 2015;20:155-62.PubMedCrossRef
111.
Mohty D, Damy T, Cosnay P, Echahidi N, Casset-Senon D, Virot P, et al. Cardiac amyloidosis: Updates in diagnosis and management. Arch Cardiovasc Dis 2013;106:528-40.PubMedCrossRef
112.
Hongo M, Urushibata K, Kai R, Takahashi W, Koizumi T, Uchikawa S, et al. Iodine-123 metaiodobenzylguanidine scintigraphic analysis of myocardial sympathetic innervation in patients with AL (primary) amyloidosis. Am Heart J 2002;144:122-9.PubMedCrossRef
113.
114.
Antoni G, Lubberink M, Estrada S, Axelsson J, Carlson K, Lindsjö L, et al. In vivo visualization of amyloid deposits in the heart with 11C-PIB and PET. J Nucl Med 2013;54:213-20.PubMedCrossRef
115.
Baughman RP, Teirstein AS, Judson MA, Rossman MD, Yeager H, Bresnitz EA, et al. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med 2001;164:1885-9.PubMedCrossRef
116.
Mehta D, Lubitz SA, Frankel Z, Wisnivesky JP, Einstein AJ, Goldman M, et al. Cardiac involvement in patients with sarcoidosis: Diagnostic and prognostic value of outpatient testing. Chest 2008;133:1426-35.PubMedCrossRef
117.
Nery PB, Mc Ardle BA, Redpath CJ, Leung E, Lemery R, Dekemp R, et al. Prevalence of cardiac sarcoidosis in patients presenting with monomorphic ventricular tachycardia. Pacing Clin Electrophysiol 2014;37:364-74.PubMedCrossRef
118.
Kandolin R, Lehtonen J, Kupari M. Cardiac sarcoidosis and giant cell myocarditis as causes of atrioventricular block in young and middle-aged adults. Circ Arrhythm Electrophysiol 2011;4:303-9.PubMedCrossRef
119.
Nery PB, Beanlands RS, Nair GM, Green M, Yang J, McArdle BA, et al. Atrioventricular block as the initial manifestation of cardiac sarcoidosis in middle-aged adults. J Cardiovasc Electrophysiol 2014;25:875-81.PubMedCrossRef
120.
Lynch JP, Hwang J, Bradfield J, Fishbein M, Shivkumar K, Tung R. Cardiac involvement in sarcoidosis: Evolving concepts in diagnosis and treatment. Semin Respir Crit Care Med 2014;35:372-90.PubMedPubMedCentralCrossRef
121.
Aggarwal NR, Snipelisky D, Young PM, Gersh BJ, Cooper LT, Chareonthaitawee P. Advances in imaging for diagnosis and management of cardiac sarcoidosis. Eur Heart J Cardiovasc Imaging 2015;16:949-58.PubMedCrossRef
122.
Blankstein R, Osborne M, Naya M, Waller A, Kim CK, Murthy VL, et al. Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoidosis. J Am Coll Cardiol 2014;63:329-36.PubMedCrossRef
123.
Kron J, Sauer W, Mueller G, Schuller J, Bogun F, Sarsam S, et al. Outcomes of patients with definite and suspected isolated cardiac sarcoidosis treated with an implantable cardiac defibrillator. J Interv Card Electrophysiol 2015;43:55-64.CrossRef
124.
Birnie DH, Sauer WH, Bogun F, Cooper JM, Culver DA, Duvernoy CS, et al. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm 2014;11:1305-23.PubMedCrossRef
125.
Betensky BP, Tschabrunn CM, Zado ES, Goldberg LR, Marchlinski FE, Garcia FC, et al. Long-term follow-up of patients with cardiac sarcoidosis and implantable cardioverter-defibrillators. Heart Rhythm 2012;9:884-91.PubMedCrossRef
126.
Kron J, Sauer W, Schuller J, Bogun F, Crawford T, Sarsam S, et al. Efficacy and safety of implantable cardiac defibrillators for treatment of ventricular arrhythmias in patients with cardiac sarcoidosis. Europace 2013;15:347-54.PubMedCrossRef
127.
Tung R, Bauer B, Schelbert H, Lynch JP, Auerbach M, Gupta P, et al. Incidence of abnormal positron emission tomography in patients with unexplained cardiomyopathy and ventricular arrhythmias: The potential role of occult inflammation in arrhythmogenesis. Heart Rhythm 2015;12:2488-98.PubMedCrossRef
128.
Wichter T, Hindricks G, Lerch H, Bartenstein P, Borggrefe M, Schober O, et al. Regional myocardial sympathetic dysinnervation in arrhythmogenic right ventricular cardiomyopathy. An analysis using 123I-meta-iodobenzylguanidine scintigraphy. Circulation 1994;89:667-83.PubMedCrossRef
129.
Wichter T, Schäfers M, Rhodes CG, Borggrefe M, Lerch H, Lammertsma AA, et al. Abnormalities of cardiac sympathetic innervation in arrhythmogenic right ventricular cardiomyopathy: Quantitative assessment of presynaptic norepinephrine reuptake and postsynaptic beta-adrenergic receptor density with positron emission tomography. Circulation 2000;101:1552-8.PubMedCrossRef
130.
Paul M, Wichter T, Kies P, Gerss J, Wollmann C, Rahbar K, et al. Cardiac sympathetic dysfunction in genotyped patients with arrhythmogenic right ventricular cardiomyopathy and risk of recurrent ventricular tachyarrhythmias. J Nucl Med 2011;52:1559-65.PubMedCrossRef
131.
Wichter T, Matheja P, Eckardt L, Kies P, Schäfers K, Schulze-Bahr E, et al. Cardiac autonomic dysfunction in Brugada syndrome. Circulation 2002;105:702-6.PubMedCrossRef
132.
Kies P, Wichter T, Schäfers M, Paul M, Schäfers KP, Eckardt L, et al. Abnormal myocardial presynaptic norepinephrine recycling in patients with Brugada syndrome. Circulation 2004;110:3017-22.PubMedCrossRef
133.
Kostopoulou A, Koutelou M, Theodorakis G, Theodorakos A, Livanis E, Maounis T, et al. Disorders of the autonomic nervous system in patients with Brugada syndrome: A pilot study. J Cardiovasc Electrophysiol 2010;21:773-80.PubMed
134.
Werner RA, Rischpler C, Onthank D, Lapa C, Robinson S, Samnick S, et al. Retention kinetics of the 18F-labeled sympathetic nerve PET tracer LMI1195: Comparison with 11C-hydroxyephedrine and 123I-MIBG. J Nucl Med 2015;56:1429-33.PubMedCrossRef
135.
Higuchi T, Yousefi BH, Kaiser F, Gartner F, Rischpler C, Reder S, et al. Assessment of the 18F-labeled PET tracer LMI1195 for imaging norepinephrine handling in rat hearts. J Nucl Med 2013;54:1142-6.PubMedCrossRef
136.
Fihn SD, Gardin JM, Abrams J, Berra K, Blankenship JC, Dallas AP, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: Executive summary a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2012;126:3097-137.PubMedCrossRef
137.
Members Task Force, Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, et al. ESC guidelines on the management of stable coronary artery disease: The task force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 2013;2013:2949-3003.
138.
McMurray JJV, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012;33:1787-847.PubMedCrossRef
139.
Mancini GBJ, Gosselin G, Chow B, Kostuk W, Stone J, Yvorchuk KJ, et al. Canadian Cardiovascular Society guidelines for the diagnosis and management of stable ischemic heart disease. Can J Cardiol 2014;30:837-49.PubMedCrossRef
140.
O’Meara E, Mielniczuk LM, Wells GA, deKemp RA, Klein R, Coyle D, et al. Alternative imaging modalities in ischemic heart failure (AIMI-HF) IMAGE HF Project I-A: Study protocol for a randomized controlled trial. Trials 2013;14:218.PubMedPubMedCentralCrossRef
Metadata
Title
The role of nuclear cardiac imaging in risk stratification of sudden cardiac death
Authors
Daniel Juneau, MD, FRCPC
Fernanda Erthal, MD
Benjamin J. W. Chow, MD, FRCPC, FACC, FASNC
Calum Redpath, MBChB, PhD
Terrence D. Ruddy, MD, FRCPC, FACC, FASNC
Juhani Knuuti, MD, PhD
Rob S. Beanlands, MD, FRCPC, FACC
Publication date
01-12-2016
Publisher
Springer US
Published in
Journal of Nuclear Cardiology / Issue 6/2016
Print ISSN: 1071-3581
Electronic ISSN: 1532-6551
DOI
https://doi.org/10.1007/s12350-016-0599-8

Other articles of this Issue 6/2016

Journal of Nuclear Cardiology 6/2016 Go to the issue

Editorial

Serial cardiac SPECT studies: Technical issues and clinical implications

News

Announcement – JNC Awards 2015-2016

Original Article

“Same-patient processing” for multiple cardiac SPECT studies. 2. Improving quantification repeatability

News

CME Instructions: Life-Threatening Ventricular Arrhythmias: Current Role of Imaging in Diagnosis and Risk Assessment

Original Article

Quantitation of left ventricular ejection fraction reserve from early gated regadenoson stress Tc-99m high-efficiency SPECT

Review Article

A quick glance at selected topics in this issue

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits